Search
KISIMA® cancer vaccine
Retinal Health
Human Pharma Clinical Pipeline Retinal Health therapeutic area
Modified yersinia
Modified yersinia
Side Effects Reporting
Side Effects Reporting
Cat diabetes infographic with key facts and figures
786214027-001_BI_Speso_NS_Infographic_Unmet-Need_2024_cc04.pdf
Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC
Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC
Second generation STING agonist
Second generation STING agonist
STING agonist (2nd generation)
Modified yersinia
Semintra®
For the management of chronic kidney disease and hypertension in cats.
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
MedInfo Mailbox List.pdf
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Our Expectations
We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
Career tips from our Global Head of HR
Sven Sommerlatte explains how important it is to reflect on the personal career strategy.
The Unwearable Collection™ Evolution
Get ready for the next stage of The Unwearable Collection™
Global mobility
We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.